OClawVPS.com
Rgenix.com
Edit

Rgenix.com

http://www.rgenix.com/
Last activity: 10.10.2018
Probably Closed - Reference to Mercusuar
Categories: BioTechDevelopmentDrugInformationInvestmentPlatformServiceUniversity
Welcome to rgenix.com
Mentions
8
Location: United States, New York
Employees: 11-50
Phone: +52 228 113 7424
Total raised: $73M
Founded date: 2010

Investors 3

Funding Rounds 2

DateSeriesAmountInvestors
09.10.2018Series C$40M-
15.06.2016Series B$33M-

Mentions in press and media 8

DateTitleDescription
10.10.2018Term Sheet — Wednesday, October 105 Qs WITH A DEALMAKER Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop “We’ve backed quite a few companies that have started as accidental businesses,” Court told Term Sheet. “The...
09.10.2018No­var­tis plans to open a string of glob­al dig­i­tal labs; Rgenix snags a $40M round in push to­ward PhII→ Vas Narasimhan has made no se­cret of his keen in­ter­est in mak­ing No­var­tis over with new dig­i­tal tech­nolo­gies, and now he plans to open new of­fices around the world to help ce­ment ties with a host of play­ers in the field, from...
09.10.2018Rgenix Raises $40M in Series C FundingRgenix, Inc., a NYC-based clinical stage biopharmaceutical company developing small molecule and antibody cancer therapeutics, raised $40m in Series C financing. The round was led by Lepu Medical, a publicly traded global healthcare firm, a...
09.10.2018Rgenix Grabs $40M Series C Financing NEW YORK, NY, Rgenix announced that it has raised $40 million in a Series C financing. >> Click here for more funding data on Rgenix >> To export Rgenix funding data to PDF and Excel, click here Rgenix, a clinical stage b...
09.10.2018Rgenix Raises $40M in Series C FundingNEW YORK--(BUSINESS WIRE)--Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced that it has raised $40 million in a Series C financing in support of fu...
15.06.2016Rgenix Raises $33 Million Series BNEW YORK--(BUSINESS WIRE)--Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing led by Novo A/S and Sofinnova Partners, with participation from exi...
15.06.2016Rgenix Announces $33M Series B NEW YORK, NY, Cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33 million Series B financing. >> Click here for more funding data on Rgenix >> To export Rgenix funding...
15.06.2016NYC-Based Cancer Therapeutics Company Rgenix Raises $33M in Series B FundingRgenix, a NYC-based cancer therapeutics company developing drugs targeting novel cancer pathways, raised $33m in Series B financing. The round was led by Novo A/S and Sofinnova Partners, with participation from existing investors including ...

Reviews 0

Sign up to leave a review

Sign up Log In